Quotient Clinical’s Translational Pharmaceutics says there will be more patient-focused development for its cancer drug research. This patient-focused angle will help reduce the lengthy and expensive early stages of drug development.
Quotient will employ its real-time, flexible manufacturing capabilities to supply specialist oncology centers with drug products to support first-in-patient and proof-of-concept programs.
Translational Pharmaceutics integrates real-time drug product manufacturing and clinical testing. This uses processes that significantly reduce the timelines and cost of early stage drug development.
Through conventional clinical drug trials the process from formulation to dosing can take up to 12 months however through Quotient Clinical development this time can be reduced to a third.
Mark Egerton, chief executive officer of Quotient Clinical, said: “We have developed our real-time manufacturing and supply capabilities to support this specialist area with first-in-patient and proof-of-concept programs.”
Clinical trials in cancer patients are becoming increasingly focused on specific patient sub-groups, which can increase the challenges of patient recruitment and the associated timelines. In turn, this can result in unpredictable drug product requirements and an inefficient supply chain.
Advantages of Quotient’s real-time manufacturing in this setting, including: flexibility, customization of drug product dose and or composition according to patient need, and increased efficiency of drug substance consumption.
Quotient Clinical deals in a variety of different drugs that include: tablets, capsules, inhaled formulations, solutions and suspensions. There is a wide market for cancer drugs and dominates the majority of pharmaceutical research that is nearly 30% of the UK.